Data / Drug companies / Desmopressin acetate
Desmopressin acetate: 27 companies and 57 products
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Desmopressin acetate is listed in the FDA National Drug Code Directory by 27 companies, with 57 products in commercial distribution. 44 of the products (77.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; tablet; injection, and the newest product started marketing on October 30, 2026.
The request: Get every company that lists desmopressin acetate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 27
- Products
- 57
- Generic (ANDA) products
- 44 (77.2%)
- Application numbers
- 19
- Routes
- Intravenous, Subcutaneous, Oral, Nasal
- Brand names
- Ddavp, Stimate
- openFDA record search
- api.fda.gov
Companies that list desmopressin acetate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Nordic Pharma, Inc. | 7 | solution; tablet | New drug applications (NDA) | May 9, 2022 |
| Ferring Pharmaceuticals Inc. | 5 | tablet; injection | New drug applications (NDA) | June 25, 2025 |
| Apotex Corp. | 3 | tablet; spray | Generic drugs (ANDA) | November 30, 2020 |
| Ubi Pharma Inc. | 3 | injection | Generic drugs (ANDA) | September 17, 2020 |
| American Health Packaging | 2 | tablet | Generic drugs (ANDA) | February 16, 2024 |
| Armas Pharmaceuticals Inc. | 2 | injection, solution | Generic drugs (ANDA) | June 30, 2026 |
| Aurobindo Pharma Limited | 2 | tablet | Generic drugs (ANDA) | March 21, 2024 |
| BluePoint Laboratories | 2 | tablet | Generic drugs (ANDA) | August 3, 2023 |
| Caplin Steriles Limited | 2 | injection, solution | Generic drugs (ANDA) | March 16, 2026 |
| Dr. Reddy's Laboratories Inc. | 2 | injection; injection, solution | Generic drugs (ANDA) | September 12, 2022 |
| Fresenius Kabi USA, LLC | 2 | injection, solution | Generic drugs (ANDA) | September 11, 2023 |
| Gland Pharma Limited | 2 | injection, solution | Generic drugs (ANDA) | March 20, 2023 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 2 | tablet | Generic drugs (ANDA) | May 26, 2017 |
| KVK-Tech, Inc. | 2 | tablet | Generic drugs (ANDA) | January 28, 2019 |
| Meitheal Pharmaceuticals Inc. | 2 | injection | Generic drugs (ANDA) | February 13, 2026 |
| Sagent Pharmaceuticals | 2 | injection, solution | Generic drugs (ANDA) | March 15, 2018 |
| Sun Pharmaceutical Industries, Inc. | 2 | injection, solution | Generic drugs (ANDA) | February 20, 2014 |
| Sun Pharmaceutical Industries, Inc. | 2 | injection, solution | Generic drugs (ANDA) | June 20, 2023 |
| The J. Molner Company LLC | 2 | injection, solution | Generic drugs (ANDA) | October 30, 2026 |
| XGen Pharmaceuticals DJB, Inc. | 2 | injection, solution | Generic drugs (ANDA) | March 22, 2024 |
| Avenacy, LLC | 1 | injection, solution | Generic drugs (ANDA) | January 15, 2024 |
| Bausch & Lomb Incorporated | 1 | solution | Generic drugs (ANDA) | January 25, 1999 |
| Bryant Ranch Prepack | 1 | tablet | Generic drugs (ANDA) | March 7, 2006 |
| Bryant Ranch Prepack | 1 | tablet | New drug applications (NDA) | December 10, 2015 |
| Northwind Health Company, LLC | 1 | tablet | Generic drugs (ANDA) | October 29, 2020 |
| Oceanside Pharmaceuticals | 1 | solution | Generic drugs (ANDA) | June 1, 2025 |
| Remedyrepack Inc. | 1 | tablet | Generic drugs (ANDA) | April 23, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 20 | 35.1% |
| Tablet | 20 | 35.1% |
| Injection | 8 | 14% |
| Solution | 7 | 12.3% |
| Spray | 2 | 3.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 44 | 77.2% |
| New drug applications (NDA) | 13 | 22.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Factor VIII Activator | 57 |
| Vasopressin Analog | 57 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.